Ionone: The Molecule that Shaped the History of Western Civilization.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 158, doi. 10.33892/aph.2021.91.158-159
- By:
- Publication type:
- Article
Works matching IS 00016659 AND DT 2021 AND VI 91 AND IP 3/4
Results: 32
1
2
Nanomedicines -- Ensuring Patient Safety through Regulatory Clarity.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 156, doi. 10.33892/aph.2021.91.156-157
- By:
- Publication type:
- Article
3
Is the Multi-Attribute Method (MAM) the Next Big Thing? A High-Resolution Accurate Mass Multi-Attribute Method for Critical Quality Attribute Monitoring.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 154, doi. 10.33892/aph.2021.91.154-155
- By:
- Publication type:
- Article
4
Advances in LC/MS for the Characterization of Biotherapeutics.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 152, doi. 10.33892/aph.2021.91.152-153
- By:
- Publication type:
- Article
5
Advanced (Multi-Dimensional) Separations for Practical Applications.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 150, doi. 10.33892/aph.2021.91.150-151
- By:
- Publication type:
- Article
6
Drugs are Absorbed in Finite Time: A New Era in Biopharmaceutics and Pharmacokinetics.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 148, doi. 10.33892/aph.2021.91.148-149
- By:
- Publication type:
- Article
7
The Gut in a Beaker: More Challenges for In Vitro Testing.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 146, doi. 10.33892/aph.2021.91.146-147
- By:
- Publication type:
- Article
8
ADMET in Drug Development: What is the Role of Animals between In Silico -- In vitro and In Vivo Humans?
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 144, doi. 10.33892/aph.2021.91.144-145
- By:
- Publication type:
- Article
9
The Relations Between Q3 Measurements, In vitro Release and TCS.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 142, doi. 10.33892/aph.2021.91.142-143
- By:
- Publication type:
- Article
10
5-Lipoxygenase: Its Noncanonical Function Unravels its Inhibitors as Powerful Antileukemic Drugs.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 140, doi. 10.33892/aph.2021.91.140-141
- By:
- Publication type:
- Article
11
Global Biosimilar Drug Development: Any Chance for Consolidation after 15 Years of Positive Regulatory Experience?
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 138, doi. 10.33892/aph.2021.91.138-139
- By:
- Publication type:
- Article
12
Regulatory Pathway for Drug-Device Combination Products in US.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 135, doi. 10.33892/aph.2021.91.135-137
- By:
- Publication type:
- Article
13
The Place of Science in the "One FIP Strategy".
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 133, doi. 10.33892/aph.2021.91.133-134
- By:
- Publication type:
- Article
14
Future of the Hungarian Drug Market -- Role of the Hungarian Regulatory Authority.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 131, doi. 10.33892/aph.2021.91.131-132
- By:
- Publication type:
- Article
15
Advances in Transdermal Drug Delivery System.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 130, doi. 10.33892/aph.2021.91.130
- By:
- Publication type:
- Article
16
Advanced Drug Delivery Systems: From Nano- and Microparticles to Smart Pills.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 128, doi. 10.33892/aph.2021.91.128-129
- By:
- Publication type:
- Article
17
Supramolecular Structure and Stability of Nanofibrous Drug Delivery Systems.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 126, doi. 10.33892/aph.2021.91.126-127
- By:
- Publication type:
- Article
18
Lipopeptide Nanoparticulate Vaccine Candidates for the Induction of Protective Immune Responses.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 124, doi. 10.33892/aph.2021.91.124-125
- By:
- Publication type:
- Article
19
An Academic Approach to Vaccine Development in a Global Pandemic: A Personal Account.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 121, doi. 10.33892/aph.2021.91.121-123
- By:
- Publication type:
- Article
20
mRNA-Lipid Nanoparticle COVID-19 Vaccines: Structure and Stability.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 120, doi. 10.33892/aph.2021.91.120
- By:
- Publication type:
- Article
21
Prodrug Nano-Squalene Bioconjugate Drug Products.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 117, doi. 10.33892/aph.2021.91.117-119
- By:
- Publication type:
- Article
22
How to Deal with Complexity of Nanomedicine in Practice.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 114, doi. 10.33892/aph.2021.91.114-116
- By:
- Publication type:
- Article
23
Same Product Different Regulatory Approach Around the World: Glatiramer Acetate.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 112, doi. 10.33892/aph.2021.91.112-113
- By:
- Publication type:
- Article
24
Complex Drugs: What Are They and Why Do They Need Special Attention?
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 110, doi. 10.33892/aph.2021.91.110-111
- By:
- Publication type:
- Article
25
How Should Synthetic Follow-Ons of Biological Products Be Regulated? What Are the Implications for Automatic Substitution?
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 108, doi. 10.33892/aph.2021.91.108-109
- By:
- Publication type:
- Article
26
Regulatory Science Challenges -- Encouraging Innovation Through an Adaptive Regulatory System.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 106, doi. 10.33892/aph.2021.91.106-107
- By:
- Publication type:
- Article
27
Drug Development Strategy in the United States: An Industrial View of DMPK.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 103, doi. 10.33892/aph.2021.91.103-105
- By:
- Publication type:
- Article
28
Regulatory Science in Drug Development.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 101, doi. 10.33892/aph.2021.91.101-102
- By:
- Publication type:
- Article
29
Merging Science and Patient in Future Drug Development to Enhance Safety and Effectiveness.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 97, doi. 10.33892/aph.2021.91.97-98
- By:
- Publication type:
- Article
30
Vaccine Development in Global Pandemic Time.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 95, doi. 10.33892/aph.2021.91.95-96
- By:
- Publication type:
- Article
31
Industry Perspectives in Modern Drug Research and Development Strategies.
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 93, doi. 10.33892/aph.2021.91.93-94
- By:
- Publication type:
- Article
32
Regulatory Perspectives -- Where We Came from, Where Are We Today, Where Are We Headed?
- Published in:
- Acta Pharmaceutica Hungarica, 2021, v. 91, n. 3/4, p. 91, doi. 10.33892/aph.2021.91.91-92
- By:
- Publication type:
- Article